NC State tapped to solve logistical challenges in Covid testing Date Published: September 15, 2020 Throughout the pandemic, the shortage of testing kits has been a persistent issue lamented by public health officials and providers…
Armed with $600K grant, NCSU researchers aim to improve COVID-19 test kit distribution Date Published: September 15, 2020 RALEIGH – Getting accurate, timely information on COVID-19 cases is one of the major challenges facing policymakers as they make…
KNOW Bio: Nitric oxide could help combat coronavirus Date Published: September 15, 2020 While vaccines have dominated the conversation about crushing coronavirus, a local company is working on a potential cure. Research Triangle…
Durham biotech startup believes its experimental treatment could fight off COVID-19 Date Published: September 14, 2020 KNOW Bio, a biotechnology startup in Research Triangle Park, has joined the raft of companies around the world trying to…
RTP startup targeting stroke treatment raises $1.9M, wants another $5M Date Published: September 11, 2020 RESEARCH TRIANGLE PARK – Life science startup Basking Biosciences, which is developing what it believes will be a reversible anti-thrombotic…
RTP biotech backed by Jim Goodnight says nitric oxide can fight COVID-19 Date Published: September 11, 2020 RESEARCH TRIANGLE PARK – KNOW Bio, a biotech backed by SAS cofounder and CEO Jim Goodnight, says it has demonstrated…
Gene therapy company bluebird bio reports positive test results for treatment Date Published: September 1, 2020 RESEARCH TRIANGLE PARK – bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled…
Triangle therapeutics startup’s deal with global firm RTI is important – here’s why Date Published: August 31, 2020 RESEARCH TRIANGLE PARK – A newly established high-powered Research Triangle Park company, APIE Therapeutics, has signed a licensing agreement with …
Durham’s BioCryst lands $44M contract to test anti-viral drug against COVID-19 virus Date Published: August 31, 2020 RESEARCH TRIANGLE PARK — BioCryst Pharmaceuticals has landed a $44 million contract to see if its investigational anti-viral drug, galidesivir,…